Editas Medicine, INC. (EDIT) — 8-K Filings

All 8-K filings from Editas Medicine, INC.. Browse 19 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (19)

8-K Filing — Mar 27, 2026
Editas Medicine Files 8-K Report — Oct 9, 2025 Risk: low
On October 9, 2025, Editas Medicine, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, along with Financial Sta
Editas Medicine Files 8-K — Sep 2, 2025 Risk: low
Editas Medicine, Inc. filed an 8-K on September 2, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, othe
Editas Medicine Files 8-K Report — Jun 12, 2025 Risk: low
On June 12, 2025, Editas Medicine, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures, other events, and financial statements and
Editas Medicine Files 8-K with Corporate Updates — Jun 2, 2025 Risk: medium
Editas Medicine, Inc. filed an 8-K on May 29, 2025, reporting on several key events. These include the departure of directors or certain officers, the election
Editas Medicine Files 8-K Report — May 14, 2025 Risk: low
On May 14, 2025, Editas Medicine, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regul
Editas Medicine Files 8-K Report — May 13, 2025 Risk: low
On May 13, 2025, Editas Medicine, Inc. filed an 8-K report. The filing primarily consists of financial statements and exhibits, with no specific material events
Editas Medicine Appoints New CFO and Directors — Mar 20, 2025 Risk: medium
Editas Medicine, Inc. announced on March 18, 2025, changes in its board and executive team. The company elected two new directors, Dr. Andrew G. Webb and Ms. Sa
Editas Medicine Files 8-K on Financials — Jan 13, 2025 Risk: low
Editas Medicine, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes information rel
Editas Medicine Announces Executive & Board Changes — Dec 17, 2024 Risk: medium
Editas Medicine, Inc. announced on December 16, 2024, a series of executive and board changes. These include the appointment of Dr. Michael A. Caligiuri as Chie
Bristol Myers Squibb to Acquire Editas Medicine for $1.5 Billion — Dec 12, 2024 Risk: medium
Editas Medicine, Inc. announced on December 11, 2024, that it has entered into a definitive agreement to be acquired by Bristol Myers Squibb Company for $4.00 p
Editas Medicine Files 8-K with Corporate Updates — Dec 10, 2024 Risk: low
Editas Medicine, Inc. filed an 8-K on December 10, 2024, reporting events as of December 6, 2024. The filing includes amendments to its articles of incorporatio
Editas Medicine Files 8-K for Financials — Nov 4, 2024 Risk: low
Editas Medicine, Inc. filed an 8-K on November 4, 2024, to report on its results of operations and financial condition, as well as to file financial statements
Editas Medicine Files 8-K on Operations and Financials — Oct 22, 2024 Risk: low
On October 22, 2024, Editas Medicine, Inc. filed an 8-K report detailing results of operations and financial condition. The filing also included Regulation FD d
Editas Medicine Files 8-K with Material Agreement — Oct 4, 2024 Risk: medium
On October 3, 2024, Editas Medicine, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also issued a Regula
Editas Medicine Announces Executive and Board Changes — Jun 27, 2024 Risk: medium
Editas Medicine, Inc. announced on June 27, 2024, the departure of its Chief Medical Officer, Dr. Michael Cheng. The company also appointed Dr. Sarah Boyce as t
Editas Medicine Files 8-K Report — Jun 14, 2024 Risk: low
On June 14, 2024, Editas Medicine, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regu
Editas Medicine Files 8-K on Shareholder Vote Matters — May 31, 2024 Risk: low
Editas Medicine, Inc. filed an 8-K on May 30, 2024, to report on matters submitted to a vote of its security holders. The filing does not detail the specific ma
Editas Medicine Files 8-K on Financials — May 8, 2024 Risk: low
Editas Medicine, Inc. filed an 8-K on May 8, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits.

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX